Association for Accessible Medicines 2025 Advocacy Priorities
WASHINGTON (February 4, 2025) — The Association for Accessible Medicines today published their 2025 advocacy priorities and regulatory and legislative reform recommendations: Protect and Defend Patient Access: The Advocacy Plan to Safeguard Affordable Generic and Biosimilar Medicines America’s patients are facing an urgent challenge that could jeopardize their access to life-saving, affordable medicines. Generics and […]
FTC Report Critical of PBMs Highlights Middlemen Profits Over Patient Savings
Interim staff report from FTC details how prescription benefit managers profit by inflating drug costs to the detriment of patients and pharmacies WASHINGTON (July 9, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, today commented on a Federal Trade Commission interim report detailing how leading pharmacy benefit […]
Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report
Featuring data from IQVIA, the 2022 U.S. Generic and Biosimilar Medicines Savings Report reveals generic and biosimilar drugs generated a record $373 billion for America’s patients and healthcare system in 2021. Despite the tremendous savings from generic drugs, many patients continue to pay more than necessary. View Report The report breaks savings down by state, […]
AAM Statement in Response to Federal Trade Commission Request for Information on PBM Business Practices
WASHINGTON, D.C. (May 23, 2022) – Today, the Association for Accessible Medicines (AAM) and its Biosimilars Council submitted a comment letter to the Federal Trade Commission in response to its request for information on the ways that large, vertically integrated Pharmacy Benefit Managers (PBMs) are affecting drug affordability and access. The FTC sought information on […]
AAM Calls for Federal Trade Commission to Investigate PBM Business Practices
On May 23, 2022, the Association for Accessible Medicines and its Biosimilars Council urged the Federal Trade Commission (FTC) to investigate the competitive impact of pharmacy benefit managers (PBMs) and their various abusive behaviors that undermine patient access to safe, affordable pharmaceutical care. In a letter responding to the FTC’s request for information “on the […]
Drug Price Transparency Bills
AAM’s core mission is to improve patients’ lives by advancing timely access to affordable, FDA-approved generic and biosimilar medicines. AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines. Our members provide more than 36,000 jobs at nearly 150 facilities, and manufacture more than 61 billion doses of […]
10 Takeaways from the Savings Report
The 10th edition of AAM’s annual generic drug savings and access report, which was released last month, is full of important data for policymakers as well as industry leaders. The report provides detailed information on savings by state, payer type, treatment area, and other factors, as well as the state of the biosimilars market. Here […]
Transparency an Important Step in Ending the Shenanigans
Congress Signals Intention to Pass Legislation Needed to End Games WASHINGTON DC (May 17, 2018) – Today, the Food and Drug Administration (FDA) for the first time publicly identified brand-name pharmaceutical companies who abuse FDA’s safety programs or erect their own restricted distribution systems without an FDA mandate to delay competition from generic and biosimilar […]
